Publications by authors named "Max Hasmann"

Claim this Profile
D
Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis.
Svenja Kemmer, Mireia Berdiel-Acer, Eileen Reinz, Johanna Sonntag, Nooraldeen Tarade, Max Hasmann

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.
Mireia Berdiel-Acer, Ana Maia, Zhivka Hristova, Simone Borgoni, Martina Vetter, Max Hasmann

Oncogene· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Denis M Collins, Stephen F Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Max Hasmann

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, Enriqueta Felip, Alejandro Navarro Mendivil, Max Hasmann

ESMO Open· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, Ulrik Lassen, Javier Cortés, Max Hasmann

Invest New Drugs· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.
Annie Moisan, Francesca Michielin, Wolfgang Jacob, Sven Kronenberg, Sabine Wilson, Max Hasmann

Mol Cancer Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Wolfgang Jacob, Ian James, Max Hasmann, Martin Weisser

Cancer Treat Rev· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions.
Ingrid Schmid, Lea Bonnington, Monika Gerl, Katrin Bomans, Anna Louisa Thaller, Max Hasmann

Commun Biol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
Pradip De, Max Hasmann, Brian Leyland-Jones

Cancer Treat Rev· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Malgorzata Magdalena Sak, Monika Szymanska, Vibeke Bertelsen, Max Hasmann, Inger Helene Madshus

Carcinogenesis· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy.
Juliane M Krüger, Marlene Thomas, René Korn, Gabriele Dietmann, Christoph Rutz, Max Hasmann

Am J Pathol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink

Mol Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab.
Juliana Bentes Hughes, Marianne Skeie Rødland, Max Hasmann, Inger Helene Madshus, Espen Stang

Pharmaceuticals (Basel)· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Dana Faratian, Annelien J M Zweemer, Yoko Nagumo, Andrew H Sims, Morwenna Muir, Max Hasmann

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann

Cancer Res· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Yoko Nagumo, Dana Faratian, Peter Mullen, David J Harrison, Max Hasmann

Mol Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
Juliana Bentes Hughes, Christian Berger, Marianne Skeie Rødland, Max Hasmann, Espen Stang

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis.
Simone Diermeier-Daucher, Max Hasmann, Gero Brockhoff

Ann N Y Acad Sci· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.
Peter Mullen, David A Cameron, Max Hasmann, John F Smyth, Simon P Langdon

Mol Cancer Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Thomas Friess, Werner Scheuer, Max Hasmann

Clin Cancer Res· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
Manickam Muruganandham, Alan A Alfieri, Cornelia Matei, Yuchun Chen, George Sukenick, Max Hasmann

Clin Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Max Hasmann, Isabel Schemainda

Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity.
Oliver J Stoetzer, Alexei Pogrebniak, Renate Pelka-Fleischer, Max Hasmann, Wolfgang Hiddemann

Biochem Pharmacol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.
Katja Wosikowski, Karin Mattern, Isabel Schemainda, Max Hasmann, Benno Rattel

Cancer Res· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis